Dosage regimen for MAdCAM antagonists
AssigneePfizer Inc.
InventorsFabio Cataldi, Robert A. Clare, Gail M. Comer, Vivekananda Pradhan, Alaa Ahmad, Mina Hassan-Zahraee, Mera Krishnan Tilley, Weidong Zhang, Anindita Banerjee, Karen Michelle Page, Michael Steven Vincent, David J. Von Schack
Life of this patent
Estimating the term…
Abstract
The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a MAdCAM antagonist antibody. Biomarkers for assessing a patient's response to anti-MAdCAM treatment are also provided.
Claims10
A method for treating ulcerative colitis in a patient comprising administering subcutaneously to the patient an initial dose of 22.5 mg of MAdCAM antagonist antibody comprising light chain SEQ ID NO:
- 1 and heavy chain SEQ ID NO:
- 2 once every 4 weeks for at least 12 weeks to achieve a clinical remission rate of at least 10% compared to baseline, wherein the clinical remission rate is determined using a MAYO score or a sccai score.
A method for treating ulcerative colitis in a patient comprising administering subcutaneously to the patient a dose of 22.5 mg of MAdCAM antagonist antibody comprising a light chain CDR1 of SEQ ID NO:11;
- a light chain CDR2 of SEQ ID NO:12;
- and a light chain CDR3 of SEQ ID NO:13;
- and
- a heavy chain CDR1 of SEQ ID NO:14;
- a heavy chain CDR2 of SEQ ID NO:15;
- and a heavy chain CDR3 of SEQ ID NO:16,
- once every 4 weeks for at least 12 weeks to achieve a clinical remission rate of at least about 10% compared to baseline, wherein the clinical remission rate is determined using a MAYO score or a sccai score.
Dependencies are inferred from the claim text.